Abeona Therapeutics unveils positive data from trial for RDEB therapy
Category: #health  By Mateen Dalal  Date: 2019-10-16
  • share
  • Twitter
  • Facebook
  • LinkedIn

Abeona Therapeutics unveils positive data from trial for RDEB therapy

Various hereditary disorders and diseases are increasingly growing across the world which need to be treated effectively. Global pharmaceutical firms are increasingly working towards finding novel solutions to address the ever-increasing occurrence of genetically-passed diseases in the world.

A recent contribution towards these efforts were made by Abeona Therapeutics, a Dallas, Texas based fully-integrated cell and gene therapy company, reportedly announced that it has published positive long term safety and efficacy results from the company’s Phase 1/2a clinical trial that evaluates a gene corrected cell treatment, EB-101, for RDEB (recessive dystrophic epidermolysis bullosa).

Treatment with EB-101 led to sustained wound healing along with a safety profile that is favorable at three years after the treatment. These follow-up long term data from seven RDEB participants whose 42 wounds were treated were further published in JCI Insight, a peer-reviewed journal.

Chief Executive Officer at Abeona, João Siffert, M.D., stated that these results strengthen the company’s belief that EB-101 is an effective and safe gene-corrected cell treatment that is capable of providing long-lasting, durable healing for the most disabling wounds in the RDEB patients.

Siffert added that these results are specifically significant, since EB-101 treatment which led to healing of the wounds even in the most challenging to address painful and large chronic wounds. Provided that the average chronic wound size in RDEB patients is more than 118 cm2, it is vital that potential novel treatments can address these wounds to enhance quality of life.

Siffert further stated that the company thanks its collaborators at Stanford as well as the patients who volunteered to participate in the trial. The company now looks forward to further build upon this robust clinical foundation with the start of its pivotal Phase 3 VIITALTM trial that would evaluate EB-101 to treat RDEB.

Vital findings from the study included wounds selected for treatment were present on the body for an average time of 11.2 years. After three years of treatment with EB-101, most of the RDEB patients had continued wound healing, with approximately 80% of wounds attaining 50% healing while 70% of wounds achieved ≥75% healing.

No serious adverse events were observed related to the treatment during the observation period of three years. Also, no replication competent virus was found at any time during treatment.

 

Source credit: https://investors.abeonatherapeutics.com/press-releases/detail/163/abeona-therapeutics-announces-publication-of-positive

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
By Mateen Dalal

Mercedes-AMG Petronas F1 Team, and Advanced Micro Devices (AMD), a renowned semiconductor developer, have reportedly announced a new multi-year partnership agreement that has combined the two firms’ passion of for high performance, beginning fr...

Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
By Mateen Dalal

The biopharmaceutical giant has also received a USD 10 million development milestone payment from Merck & CO. for the initiation of the trial A clinical-stage biopharmaceutical company, Aduro Biotech, Inc. recently announced to have ba...

TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
By Mateen Dalal

TherapeuticsMD, Inc., an inventive pharmaceutical company that focuses on women healthcare, has recently announced that it has presented a New Drug Application (NDA) pre-approval efficacy supplement to the U.S. FDA (Food and Drug Administration) for ...